Search Results

Molecular Templates, Inc. today provided an update on its clinical-stage programs.

Molecular Templates, Inc. today provided an update on its programs.

Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Molecular Templates, Inc. announced participation in the following upcoming investor conferences.

BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2023.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM’s outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV.